An official website of the United States government
Home
Name
Blenrep
Alternate Names
belantamab mafodotin-blmf
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
None
Histology
Multiple myeloma
Remarks
August 5, 2020 The FDA approved belantamab mafodotin-blmf (Blenrep) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Coding
This drug should be coded
